Antiarrhythmic profile and endothelial action of novel decahydroquinoline derivatives

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 767-774

  Kozlovski, Valery I ^a,b   Vdovichenko, Vladimir P ^b   Chłopicki, Stefan ^a   Malchik, Sergey S ^b   Praliyev, Kaldybek D ^c   Zcilkibayev, Oral T ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

^c Institute of Chemical Sciences Academy of Sciences of Kazakhstan   (Kazakhstan)

Author keywords

Antiarrhythmic; Coronary vasodilation; Decahydroquinoline; Endothelium; Nitric oxide

Indexed keywords

ACONITINE; ADRENALIN; ANTIARRHYTHMIC AGENT; CALCIUM CHLORIDE; DECAHYDROQUINOLINE DERIVATIVE; LIDOCAINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG STRUCTURE; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART LEFT VENTRICLE DP-DT; ISOLATED HEART; LD 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ACONITINE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; CALCIUM CHLORIDE; CORONARY VESSELS; EPINEPHRINE; FEMALE; GUINEA PIGS; MALE; MOLECULAR STRUCTURE; NITRIC OXIDE; QUINOLINES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATION;

EID: 14244263021     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Abrams J: Role of endothelial dysfunction in coronary artery disease. Am J Cardiol, 1997, 79, 2-9.
2. Alexanian AR, Arutyunian NS, Galoyan AA: Antiarrhythmic action of the new calcium antagonist [1,2,5-trimethyl-4-phenyl-4-beta-(N-cyanoethyl-N-4′-methoxybenzyl) -ethylamino]piperidine dihydrochloride. Arzneimittelforschung, 1996, 46, 1110-1113.
3. Allan G, Donoghue S, Follenfant MJ, Sawyer DA: BW A256C, a chemically novel class 1 antiarrhythmic agent. A comparison of in vitro and in vivo activity with other class 1 antiarrhythmic agents. Br J Pharmacol, 1986, 88, 333-343.
4. Ashrafian H, Davey P: Is amiodarone an underrecognized cause of acute respiratory failure in the ICU? Chest, 2001, 120, 275-282.
5. Bagwell EE, Polster P, Williams EM: The effects on cardiac muscle and nerve of a fluorinated decahydroquinoline derivative, L7810, rapidly absorbed after oral administration. Br J Pharmacol, 1973, 48, 183-193.
6. Britten MB, Zeiher AM, Schachinger V: Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med, 1999, 245, 315-327.
7. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol, 1990, 16, 1711-1718.
8. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet, 1997, 349, 675-682.
9. Chen YJ, Tsai CF, Chiou CW, Chan P, Chen SA: Effect of nitric oxide on strophanthidin-induced ventricular tachycardia. Pharmacology, 2001, 62, 213-217.
10. Chłopicki S, Gryglewski RJ: Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea pig heart. Eur J Pharmacol, 1993, 241, 117-120.
11. Cobbe SM: Class III antiarrhythmics: put to the SWORD? Heart, 1996, 75, 111-113.
12. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, Heger JJ: Clinical features of amiodarone-induced pulmonary toxicity. Circulation, 1990, 82, 51-59.
13. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. In: The Cardiac Arrhythmia Suppression Trial, 1991.
14. Filipek B, Krupińska J, Zebala K, Szymańska I, Librowski T, Piekoszewski W: Influence of ethanol on the antiarrhythmic activity of verapamil. Pol J Pharmacol Pharm, 1992, 44, 443-452.
15. Gonon AT, Gourine AV, Pernow J: Cardioprotection from ischemia and reperfusion injury by an endothelin A-receptor antagonist in relation to nitric oxide production. J Cardiovasc Pharmacol, 2000, 36, 405-412.
16. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M: Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation, 1990, 81, 860-864.
17. Gottlieb SS, Riggio DW, Lauria S, Peters RW, Shorofsky SR, Cines M, Froman D et al.: High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol, 1994, 23, 560-564.
18. Gutierrez B, Vilumara A, Farre AJ: Inhibition of aconitine-induced mortality in the conscious rat: a screening test for antiarrhythmic drugs. Methods Find Exp Clin Pharmacol, 1987, 9, 307-310.
19. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet, 1997, 349, 667-674.
20. Kamei J, Mori T, Ogawa M, Kasuya Y: Subsensitivity to the cough-depressant effects of opioid and nonopioid antitussives in morphine-dependent rats: relationship to central serotonin function. Pharmacol Biochem Behav, 1989, 34, 595-598.
21. Karpitskii VV, Slovesnov SV, Rerikh RA: Determination of cardiac output in small laboratory animals by tetrapolar rheography (Russ). Patol Fiziol Eksp Ter, 1986, 1, 74-77.
22. Librowski T, Filipek B, Czarnecki R: Local anesthetic and antiarrhythmic effect of some imidazolidin-2-one derivatives. Acta Pol Pharm, 2000, 57, 391-396.
23. Lu HR, Remeysen P, De Clerck F: Does the antiarrhythmic effect of ischemic preconditioning in rats involve the L-arginine nitric oxide pathway? J Cardiovasc Pharmacol, 1995, 25, 524-530.
24. Mayer DB, Miletich DJ, Feld JM, Albrecht RF: The effects of magnesium salts on the duration of epinephrine-induced ventricular tachyarrhythmias in anesthetized rats. Anesthesiology, 1989, 71, 923-928.
25. Mouille P, Schmitt H, Cheymol G, Gauter E: Cardiovascular and beta-adrenergic blocking effects of timolol. Eur J Pharmacol, 1976, 35, 235-243.
26. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, de-Marchena E, Interian A Jr, Castellanos A: Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med, 1992, 326, 1451-1455.
27. Nilius B, Benndorf K, Markwardt F: Modified gating behavior of aconitine-treated single sodium channels from adult cardiac myocytes. Pflugers Arch, 1986, 407, 691-693.
28. Peper K, Trautwein W: The effect of aconitine on the membrane current in cardiac muscle. Pflugers Arch Gesamte Physiol Menschen Tiere, 1967, 296, 328-336.
29. Podrid PJ: Amiodarone: reevaluation of an old drug. Ann Intern Med, 1995, 122, 689-700.
30. Pogwizd SM, Corr B: The contribution of nonreentrant mechanisms to malignant ventricular arrhythmias. Basic Res Cardiol, 1992, 87, Suppl 2, 115-129.
31. Praliyev KD, Fishchuk EV, Malchikova LS: Synthesis and cardiotropic activity of new derivatives of two stereoisomers of 1-[2-(3,4-dimethoxyphenyl-ethyl ]-2-methyl-4-ethynyl-4-oxy-trans-decahydroquinoline. Chem Pharm J, 1989, 8, 939-941.
32. Praliyev KD, Fishchuk EV, Rozhnov VB et al.: Synthesis, stereochemistry and pharmacologic activity of 1-[2-(3,4-dimethoxyphenyi-ethyl)]-2-methyl4-keto-decahydroquinoline and corresponding acetylene alcohols. Chem Pharm J, 1989, 8, 931-935.
33. Prost M, Urbain M, Houben C, Schumer A, Van Cromphaut V, Van Meerbeek C, Verstraeten W et al.: Derivatives of decahydroquinoline. Study and pharmacologic screening of carbamates and esters of N-benzoylalkylated 4-hydroxy decahydroquinolines and corresponding dioxane compound. Ann Pharm Fr, 1985, 43, 139-146.
34. Raeder EA, Podrid PJ, Lown B: Side effects and complications of amiodarone therapy. Am Heart J, 1985, 109, 975-983.
35. Ruskin JN: The cardiac arrhythmia suppression trial (CAST). N Engl J Med, 1989, 321, 386-388.
36. Stella L, de Novellis V, Vacca C, Guarino A, Cantoni V, Fici F, Rossi F: Antiarrhythmic effects of LR-A /113, a new calcium antagonistic drug. Res Commun Mol Pathol Pharmacol, 1996, 93, 235-248.
37. Takahara A, Uneyama H, Sasaki N, Ueda H, Dohmoto H, Shoji M, Hara Y et al.: Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents. J Cardiovasc Pharmacol, 1999, 33, 625-632.
38. Tanz RD: Pharmacology of aconitine-induced automaticity on in vitro cat myocardial preparations. II. Effects of refractory period prolongation, reduced sodium and tetrodotoxin. J Pharmacol Exp Ther, 1974, 191, 232-240.
39. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA, 1993, 270, 1589-1595.
40. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet, 1996, 348, 7-12.
41. Winslow E: Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity. Br J Pharmacol, 1980, 71, 615-622.
42. Winslow E: Hemodynamic and arrhythmogenic effects of aconitine applied to the left atria of anesthetized cats. Effects of amiodarone and atropine. J Cardiovasc Pharmacol, 1981, 3, 87-100.
43. Yoshidomi M, Sukamoto T, Morita T, Ito K, Nose T: Antiarrhythmic effect of KB-944, a new calcium antagonist. A comparison with verapamil and diltiazem. Arzneimittelforschung, 1982, 32, 1056-1059.